Intermittent Radioligand Therapy with (177)Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer

SIMPLE SUMMARY: Radioligand therapy (RLT) usually consists of predefined cycles of (177)Lu-PSMA-617 every 6–8 weeks. Although side-effects of RLT are considered well tolerable, cumulative absorbed doses in kidneys and an increased probability of chronic renal failure in responders remain concerns. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Mader, Nicolai, Schoeler, Christina, Pezeshkpour, Niloufar, Klimek, Konrad, Groener, Daniel, Happel, Christian, Tselis, Nikolaos, Mandel, Philipp, Grünwald, Frank, Sabet, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527374/
https://www.ncbi.nlm.nih.gov/pubmed/37760574
http://dx.doi.org/10.3390/cancers15184605

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10527374/
https://www.ncbi.nlm.nih.gov/pubmed/37760574
http://dx.doi.org/10.3390/cancers15184605

Ejemplares similares